Literature DB >> 10672467

Effects of systemic 3-nitropropionic acid-induced lesions of the dorsal striatum on cannabinoid and mu-opioid receptor binding in the basal ganglia.

K J Page1, L Besret, M Jain, E M Monaghan, S B Dunnett, B J Everitt.   

Abstract

Systemic administration of 3-nitropropionic acid (3NPA) in experimental animals produces bilateral striatal lesions similar to those seen in Huntington's disease (HD) caudate and putamen. 3H[-CP55,940 binding to cannabinoid receptors in human basal ganglia nuclei has been shown to be highly susceptible to the earliest pathological changes in the HD brain. In this study, to assess further the suitability of 3NPA-induced striatal lesions as a model for HD neuropathology, we examined the effects of striatal lesions induced by the systemic administration of 3NPA on the binding of 3H[-CP55,940 to pre- and postsynaptic cannabinoid receptors in striatum, globus pallidus, entopeduncular nucleus and substantia nigra pars reticulata and also the effect of 3NPA-induced striatal lesions on the binding of 3H[-DAMGO to mu-opioid receptors in striatal striosomes. Systemic administration of 3NPA induced bilateral and symmetrical lesions in dorsolateral striatum. Within the lesion core, 3H[-CP55,940 and 3H[-DAMGO binding density was reduced to background levels. Beyond the immediate borders of the central core of the 3NPA-induced lesion, striatal binding density was not significantly different from that measured in unlesioned rats. 3H[-CP55,940 binding in globus pallidus, entopeduncular nucleus and substantia nigra in 3NPA-lesioned rats was significantly reduced compared to controls, and the individual decreases were similar for each site. However, these reductions were statistically marginal. These data suggest that, while producing striatal lesions which bear some similarity to those seen in HD, the consequences of 3NPA for striatopallidal and striatonigral efferent projections do not reflect the reported neurodegenerative changes seen in the HD brain.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10672467     DOI: 10.1007/s002210050016

Source DB:  PubMed          Journal:  Exp Brain Res        ISSN: 0014-4819            Impact factor:   1.972


  10 in total

1.  Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat Caudate putamen nucleus.

Authors:  J J Rodriguez; K Mackie; V M Pickel
Journal:  J Neurosci       Date:  2001-02-01       Impact factor: 6.167

2.  Loss of cannabinoid CB(1) receptors in the basal ganglia in the late akinetic phase of rats with experimental Huntington's disease.

Authors:  Isabel Lastres-Becker; María Gómez; Rosario De Miguel; José A. Ramos; Javier Fernández-Ruiz
Journal:  Neurotox Res       Date:  2002 Nov-Dec       Impact factor: 3.911

Review 3.  The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids.

Authors:  Roger G Pertwee
Journal:  AAPS J       Date:  2005-10-24       Impact factor: 4.009

4.  Oxidative damage and sensitivity to nociceptive stimulus and opioids in aging rats.

Authors:  Atul Raut; Anna Ratka
Journal:  Neurobiol Aging       Date:  2007-11-07       Impact factor: 4.673

5.  Neuroprotective effect of WIN55,212-2 against 3-nitropropionic acid-induced toxicity in the rat brain: involvement of CB1 and NMDA receptors.

Authors:  Marisol Maya-López; Ana Laura Colín-González; Gabriela Aguilera; María Eduarda de Lima; Ana Colpo-Ceolin; Edgar Rangel-López; Juana Villeda-Hernández; Daniel Rembao-Bojórquez; Isaac Túnez; Armando Luna-López; Roberto Lazzarini-Lechuga; Viridiana Yazmín González-Puertos; Pedro Posadas-Rodríguez; Alejandro Silva-Palacios; Mina Königsberg; Abel Santamaría
Journal:  Am J Transl Res       Date:  2017-02-15       Impact factor: 4.060

Review 6.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

Review 7.  Huntington's disease and Group I metabotropic glutamate receptors.

Authors:  Fabiola M Ribeiro; Rita G W Pires; Stephen S G Ferguson
Journal:  Mol Neurobiol       Date:  2010-12-09       Impact factor: 5.590

Review 8.  Biosynthesis of endocannabinoids and their modes of action in neurodegenerative diseases.

Authors:  Mario van der Stelt; Henrik H Hansen; Wouter B Veldhuis; Peter R Bär; Klaas Nicolay; Gerrit A Veldink; Johannes F G Vliegenthart; Harald S Hansen
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

9.  Intracerebral transplantation of neural stem cells combined with trehalose ingestion alleviates pathology in a mouse model of Huntington's disease.

Authors:  Chia-Ron Yang; Robert K Yu
Journal:  J Neurosci Res       Date:  2009-01       Impact factor: 4.164

Review 10.  The endocannabinoid system as a target for the treatment of motor dysfunction.

Authors:  Javier Fernández-Ruiz
Journal:  Br J Pharmacol       Date:  2009-02-13       Impact factor: 8.739

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.